Richard J Goldstein

US Patent:

6630302, Oct 7, 2003

Filed:

Apr 4, 2000

Appl. No.:

09/463588

Inventors:

Richard N. Goldstein - Cambridge MA

Assignee:

The Trustees of Boston University - Boston MA

International Classification:

C12Q 168

US Classification:

435 6, 435 5, 435 29, 435 34, 435 39, 435804, 435822, 435196, 536 243, 536 2432

Abstract:

Methods and compositions are described for methods and compositions for determining the species for an unknown bacterium (or fungus) in a sample. The approach, which utilizes Ribosomal operon sequences, permits one to identify important bacteria (or fungi) pathogens in a clinical setting.

US Patent:

6673538, Jan 6, 2004

Filed:

Apr 21, 2000

Appl. No.:

09/463587

Inventors:

Richard N. Goldstein - Cambridge MA

Assignee:

The Trustees of Boston University - Boston MA

International Classification:

C12Q 168

US Classification:

435 6, 435243

Abstract:

Methods and compositions are described for determining a statistically significant number of different strains within a species of bacteria indicative of the species population structure as a whole in order to permit the evaluation of a vaccine target.

US Patent:

43329012, Jun 1, 1982

Filed:

Feb 27, 1978

Appl. No.:

5/881170

Inventors:

Richard N. Goldstein - Cambridge MA

Assignee:

President and Fellows of Harvard College - Cambridge MA

International Classification:

C12N 700
C12N 1500

US Classification:

435235

Abstract:

A cloning vector useful in recombining DNA (i. e. recombinant DNA studies) is made by mutagenesis of a satellite bacteriophage P4 wt or P4 vir. sub. 1 and subsequent separation and purification of the mutant progeny in a cesium chloride equilibrium density gradient. On such a cesium chloride gradient the mutant is found in a range of densities from 1. 35 to 1. 42 g/ml at 24. degree. C. with peaks at about 1. 42, 1. 39, and 1. 35 g/ml.

US Patent:

44156600, Nov 15, 1983

Filed:

Mar 12, 1982

Appl. No.:

6/357414

Inventors:

Richard N. Goldstein - Cambridge MA

Assignee:

President and Fellows of Harvard College - Cambridge MA

International Classification:

C12N 1500

US Classification:

435172

Abstract:

A cloning vector useful in recombining DNA (i. e. recombinant DNA studies) is made by mutagenesis of a satellite bacteriophage P4 wt or P4 vir. sub. 1 and subsequent separation and purification of the mutant progeny in a cesium chloride equilibrium density gradient. On such a cesium chloride gradient the mutant is found in a range of densities from 1. 35 to 1. 42 g/ml at 24. degree. C. with peaks at about 1. 42, 1. 39, and 1. 35 g/ml.

US Patent:

20200085932, Mar 19, 2020

Filed:

Nov 19, 2019

Appl. No.:

16/688545

Inventors:

- Boston MA, US
Richard N. Goldstein - Cambridge MA, US

International Classification:

A61K 39/09
A61P 31/04

Abstract:

Cold spot genes of are disclosed that encode surface proteins that are universally conserved among known strains and have exceptionally low incidence of allelic variation. Cold spot polypeptides encoded by the genes that are antigenic on the cells on which they are expressed are candidates for immunogenic compositions capable of eliciting antibodies able to react with all or nearly all strains of , thus providing an improvement over currently available vaccines that protect inoculated individuals against a maximum of about 23 of the 94 or so known serotypes of

US Patent:

20180280493, Oct 4, 2018

Filed:

Mar 29, 2018

Appl. No.:

15/939850

Inventors:

- Boston MA, US
Richard N. GOLDSTEIN - Cambridge MA, US

International Classification:

A61K 39/09
A61P 31/04

Abstract:

Cold spot genes of are disclosed that encode surface proteins that are universally conserved among known strains and have exceptionally low incidence of allelic variation. Cold spot polypeptides encoded by the genes that are antigenic on the cells on which they are expressed are candidates for immunogenic compositions capable of eliciting antibodies able to react with all or nearly all strains of thus providing an improvement over currently available vaccines that protect inoculated individuals against a maximum of about 23 of the 94 or so known serotypes of